Advance of Research on the Immunotherapy Targeting B Cell Maration Antigen for Multiple Myeloma--Review / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 1701-1705, 2019.
Artículo
en Chino
| WPRIM
| ID: wpr-775662
ABSTRACT
Abstract B cell maturation antigen (BCMA) is an ideal target for precise treatment due to its highly selective expression on malignant myeloma cells. This review summarizes briefly the advances in the latest research progress on biological activity of BCMA, its significance as a biomarker and immunotherapy direcited against BCMA, such as bispecific antibodies, antibody drug conjugates, chimeric antigen receptor T cell therapy against mature B cell antigens.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Terapéutica
/
Linfocitos B
/
Linfocitos T
/
Antígenos de Diferenciación de Linfocitos B
/
Antígeno de Maduración de Linfocitos B
/
Inmunoterapia
/
Mieloma Múltiple
Límite:
Humanos
Idioma:
Chino
Revista:
Journal of Experimental Hematology
Año:
2019
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS